Lead sponsor
Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
2 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
2
Trials led
1
Active
846
Total enrollment
37
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 3
2
Trials by status
Not yet recruiting
1
Completed
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes MellitusHbA1c ≥7%Ph 3Completed476
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®BMI ≥28Ph 3Not yet recruiting370